256 related articles for article (PubMed ID: 35078378)
1. Biosimilar development and review process in the BRICS-TM countries: Proposal for a standardized model to improve regulatory performance.
Rahalkar H; Sheppard A; Salek S
Expert Rev Clin Pharmacol; 2022 Feb; 15(2):215-236. PubMed ID: 35078378
[TBL] [Abstract][Full Text] [Related]
2. Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices.
Rahalkar H; Sheppard A; Salek S
Front Pharmacol; 2021; 12():711361. PubMed ID: 34434109
[No Abstract] [Full Text] [Related]
3. Challenges Faced by the Biopharmaceutical Industry in the Development and Marketing Authorization of Biosimilar Medicines in BRICS-TM Countries: An Exploratory Study.
Rahalkar H; Sheppard A; Lopez-Morales CA; Lobo L; Salek S
Pharmaceut Med; 2021 Jul; 35(4):235-251. PubMed ID: 34292558
[TBL] [Abstract][Full Text] [Related]
4. Current Regulatory Requirements for Biosimilars in Six Member Countries of BRICS-TM: Challenges and Opportunities.
Rahalkar H; Sheppard A; Santos GML; Dasgupta C; Perez-Tapia SM; Lopez-Morales CA; Salek S
Front Med (Lausanne); 2021; 8():726660. PubMed ID: 34568384
[No Abstract] [Full Text] [Related]
5. Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines.
Rahalkar H; Cetintas HC; Salek S
Front Pharmacol; 2018; 9():1079. PubMed ID: 30364154
[No Abstract] [Full Text] [Related]
6. Considerations related to comparative clinical studies for biosimilars.
Rathore AS; Stevenson JG; Chhabra H
Expert Opin Drug Saf; 2021 Mar; 20(3):265-274. PubMed ID: 33455482
[No Abstract] [Full Text] [Related]
7. Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
Rivera VM
Neurol Ther; 2019 Dec; 8(2):177-184. PubMed ID: 31313222
[TBL] [Abstract][Full Text] [Related]
8. Regulatory Perspective of International Agencies for Development of Biosimilar Products (Monoclonal Antibodies): An Overview.
Sharma A; Khante S; Mahadik KR; Gaikwad VL
Ther Innov Regul Sci; 2020 Sep; 54(5):965-977. PubMed ID: 31933180
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products.
Moore TJ; Mouslim MC; Blunt JL; Alexander GC; Shermock KM
JAMA Intern Med; 2021 Jan; 181(1):52-60. PubMed ID: 33031559
[TBL] [Abstract][Full Text] [Related]
10. WHO guidelines on biosimilars: Toward improved access to safe and effective products.
Kang HN; Wadhwa M; Knezevic I; Ondari C; Simao M
Ann N Y Acad Sci; 2023 Mar; 1521(1):96-103. PubMed ID: 36694455
[TBL] [Abstract][Full Text] [Related]
11. Comparability and biosimilarity: considerations for the healthcare provider.
Lee JF; Litten JB; Grampp G
Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
[TBL] [Abstract][Full Text] [Related]
12. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®.
Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR
Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209
[TBL] [Abstract][Full Text] [Related]
13. Understanding the biosimilar approval and extrapolation process-A case study of an epoetin biosimilar.
Agarwal AB; McBride A
Crit Rev Oncol Hematol; 2016 Aug; 104():98-107. PubMed ID: 27317353
[TBL] [Abstract][Full Text] [Related]
14. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
[TBL] [Abstract][Full Text] [Related]
15. The process defines the product: what really matters in biosimilar design and production?
Vulto AG; Jaquez OA
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv14-iv29. PubMed ID: 28903544
[TBL] [Abstract][Full Text] [Related]
16. Development of biosimilars.
Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
[TBL] [Abstract][Full Text] [Related]
17. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
18. Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009-2022.
Kuribayashi R; Nakano A; Hariu A; Kishioka Y; Honda F
BioDrugs; 2023 Jul; 37(4):443-451. PubMed ID: 37227657
[TBL] [Abstract][Full Text] [Related]
19. Considerations in the early development of biosimilar products.
Li EC; Abbas R; Jacobs IA; Yin D
Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
